Karl Hård
Investor Relations Kontakt bei EGETIS THERAPEUTICS AB
Aktive Positionen von Karl Hård
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EGETIS THERAPEUTICS AB | Investor Relations Kontakt | 01.02.2022 | - |
| Public Communications Contact | 01.02.2022 | - |
Karriereverlauf von Karl Hård
Ehemalige bekannte Positionen von Karl Hård
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KIADIS PHARMA N.V. | Investor Relations Kontakt | 05.09.2017 | 31.12.2018 |
| Public Communications Contact | 05.09.2017 | 31.12.2018 | |
| REDX PHARMA PLC | Investor Relations Kontakt | 08.09.2016 | 02.07.2017 |
| Public Communications Contact | 08.09.2016 | 02.07.2017 | |
| University of Leiden | Corporate Officer/Principal | - | - |
| ASTRAZENECA PLC | Public Communications Contact | - | - |
Ausbildung von Karl Hård
| University of Utrecht | Doctorate Degree |
| University of Helsinki | Graduate Degree |
Statistik
International
| Niederlande | 4 |
| Vereinigtes Königreich | 3 |
| Finnland | 2 |
Operativ
| Public Communications Contact | 4 |
| Investor Relations Contact | 3 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 4 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| REDX PHARMA PLC | Health Technology |
| EGETIS THERAPEUTICS AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Kiadis Pharma NV
 Kiadis Pharma NV Pharmaceuticals: MajorHealth Technology Kiadis Pharma NV engages in pharmaceutical development of cell-based immunotherapy products in the field of diseases of the blood building system. Its lead product is the ATIR101. The company was founded in 1997 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
